Company Overview
Kodiak Sciences is a precommercial biotechnology company focused on researching, developing, and commercializing transformative therapeutics for retinal diseases.
Key Financial Figures
For the fourth quarter of 2025, the reported net loss per share (EPS) was $(1.04). The full-year 2025 net loss per share (EPS) was $(4.32). Revenue is not reported in the provided financial statements.
Additional Financial Insights
Kodiak ended 2025 with $209.9 million in cash and cash equivalents. Full-year research and development expenses reached $182.4 million, primarily driven by active clinical studies. Furthermore, a December 2025 equity offering generated $173.0 million in net proceeds, which the company believes will support planned operations into 2027.